Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hypoglycemia has been associated with an increased risk of cardiovascular (CV) events and all-cause mortality. This study assessed whether, in a nationally representative population, there is an association between hypoglycemia, the risk of CV events, and all-cause mortality among insulin-treated people with type 1 diabetes or type 2 diabetes. RESEARCH DESIGN AND METHODS: This retrospective cohort study used data from the Clinical Practice Research Datalink database and included all insulin-treated patients (≥30 years of age) with a diagnosis of diabetes. RESULTS: In patients who experienced hypoglycemia, hazard ratios (HRs) for CV events in people with type 1 diabetes were 1.51 (95% CI 0.83, 2.75; P = ns) and 1.61 (1.17, 2.22), respectively, for those with and without a history of CV disease (CVD) before the index date. In people with type 2 diabetes, the HRs for patients with and without a history of CVD were 1.60 (1.21, 2.12) and 1.49 (1.23, 1.82), respectively. For all-cause mortality, HRs in people with type 1 diabetes were 1.98 (1.25, 3.17), and 2.03 (1.66, 2.47), respectively, for those with and without a history of CVD. Among people with type 2 diabetes, HRs were 1.74 (1.39, 2.18) and 2.48 (2.21, 2.79), respectively, for those with and without a history of CVD. The median time (interquartile range) from first hypoglycemia event to first CV event was 1.5 years (0.5, 3.5 years) and 1.5 years (0.5, 3.0 years), respectively, for people with type 1 and type 2 diabetes. CONCLUSIONS: Hypoglycemia is associated with an increased risk of CV events and all-cause mortality in insulin-treated patients with diabetes. The relationship between hypoglycemia and CV outcomes and mortality exists over a long period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CVD mortality accounts for 30-44% of all deaths in patients with T1DM.[780][781][782][783][784]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“People with T1DM face a three-fold increase in mortality compared with the general population”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“which translates into an 11-year reduction in life expectancy”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“multiple studies have shown a strong relationship between hypoglycemia (severe or not severe) and cardiovascular events and mortality”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [200]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Since the ACCORD and VADT results were published, attempts have been made to assess whether a relationship exists between hypoglycemia and CV risk or mortality, but only recently has a consensus begun to emerge suggesting that there is a link between the two (6,8,9).”
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Cited by
Items 201–300 of 355
Martín, Zhou, Y., Takagi, T., & Tian, Y. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01410-x · Cited by 11
Hughes, A. S., CHAPMAN, K. S. M., Nguyen, H., Liu, J., Bispham, J. A., Winget, M., WEINZIMER, S. A., & Wolf, W. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0099 · Cited by 10
“disease (CVD) in people with type 1 diabetes (8,9), which”
BackgroundChaudhry, U. A. R., Carey, I. M., Critchley, J., DeWilde, S., Limb, E. S., Bowen, L., Panahloo, A., Cook, D. G., Whincup, P. H., & Harris, T. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111023 · Cited by 9
Kugathasan, L., Sridhar, V. S., Lovblom, L. E., Matta, S., Saliba, A., Debnath, S., Alakwaa, F., Nair, V., Bjornstad, P., Kretzler, M., et al. (2023) · Diabetes · doi:10.2337/db23-0694 · Cited by 10
Bushey, E. L., Wu, Y., Wright, A. J., & Pescatello, L. S. (2024) · Journal of Medical Internet Research · doi:10.2196/51321 · Cited by 9
“Consistent with our findings, other studies have shown that even modest reductions in anthropometric CVD risk factor outcomes (ie, body weight, BMI, and waist circumference) can lead to clinically important improvements in other CVD risk factor outcomes [17,53-55].”
Russel-Szymczyk, M., Valov, V., Savova, A., & Manova, M. M. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0460-6 · Cited by 10
Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes
Ren, Q., Xiao, D., Han, X., Edwards, S. L., Wang, H., Tang, Y. C., Zhang, S., Li, X., Zhang, X., Cai, X., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0427 · Cited by 9
Self-citationFactors Influencing Variations in Hospitalization for Diabetes with Hypoglycemia
Kattan, W., & Wan, T. T. H. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100367 · Cited by 11
McCoy, R. G., SWARNA, K. S., Neumiller, J. J., Polley, E. C., Deng, Y., Mickelson, M. M., & Herrin, J. S. (2024) · Clinical Diabetes · doi:10.2337/cd24-0007 · Cited by 8
Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
Stougiannou, T. M., Christodoulou, K. C., Koufakis, T., Mitropoulos, F. A., Mikroulis, D. A., Mazer, C. D., & Karangelis, D. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904145 · Cited by 11
Kugathasan, L., Sridhar, V. S., Lytvyn, Y., Lovblom, L. E., Perkins, B. A., Advani, A., & Cherney, D. Z. I. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111764 · Cited by 8
McCoy, R. G., Lipska, K. J., Houten, H. K. V., & Shah, N. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001878 · Cited by 7
Nomoto, H., Oba‐Yamamoto, C., Takahashi, Y., Takeuchi, J., Nagai, S., Yokoyama, H., Taneda, S., Kurihara, Y., Aoki, S., Kameda, H., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00986-9 · Cited by 9
Quirós, C., Viñals, C., Giménez, M., Roca, D., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.03.009 · Cited by 7
Drummond, J., Soares, B. S., Vieira, É. L. M., Pedrosa, W., Teixeira, A. L., & Ribeiro‐Oliveira, A. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577446 · Cited by 10
Fährmann, E. R., ADKINS, L. J., & Driscoll, H. K. (2021) · Diabetes Care · doi:10.2337/dc20-2757 · Cited by 10
Ali, N., Janssen, A. W. M., Jaeger, M., de Wijer, L. V., van der Heijden, W., ter Horst, R., Vart, P., van Gool, A. J., Joosten, L. A. B., Netea, M. G., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14172 · Cited by 9
Nimri, R., Murray, N., Ochs, A., Pinsker, J. E., & Dassau, E. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.2504 · Cited by 8
Chan, S. P., Lim, L., Chan, J. C. N., & Matthews, D. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01386-5 · Cited by 10
“However, hypoglycaemia and therapeutic inertia are major barriers in achieving optimal glycaemic control [18].”
BackgroundPaul, S. K., & Samanta, M. (2015) · International Journal of Statistics in Medical Research · doi:10.6000/1929-6029.2015.04.02.4 · Cited by 7
“Hypoglycaemia, in which blood glucose levels become unacceptably low, can lead to acute mental and physical impairment with possible progression to coma if not treated promptly, and repeated episodes confer an increased risk of future cardiovascular events [1].”
BackgroundSelf-citationGómez, A. M., Madero, A. I., Henao, D. C., Maira, G., Giménez, M., Viñals, C., Grassi, B. A., Torres, M., Zuluaga, I., Múñoz, Ó., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.01.002 · Cited by 7
The phenomenon of HbA1c stability and the risk of hypoglycemia in long-standing type 1 diabetes
Wolnik, B., Orłowska-Kunikowska, E., Błaszkowska, M., Graff, B., Wolf, J., Czupryniak, L., & Narkiewicz, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.010 · Cited by 7
Available at a flash: a new way to check glucose
Thabit, H., Bally, L., & Hovorka, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31582-3 · Cited by 7
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177283 · Cited by 7
Fujikawa, T., Ohara, M., Kohata, Y., Nagaike, H., Fukase, A., Osaka, N., Yashima, H., Sato, N., Kushima, H., Shinmura, K., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01008-y · Cited by 6
Brunetti, V. C., Yu, O. H. Y., Platt, R. W., & Filion, K. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14802 · Cited by 7
Mesa, A., Giménez, M., Perea, V., Serés‐Noriega, T., Boswell, L., Blanco, J., Milad, C., Pané, A., Esmatjes, E., Vinagre, I., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3785 · Cited by 7
“Although retrospective studies in this population have associated hypoglycemia with an increased risk of CVD events, 32–34 no association was found between baseline SH events and incidence of CVD in the EURODIAB Prospective Complications Study.”
BackgroundZaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Gray, L. J., Chatterjee, S., Housley, G., Shaw, D. E., Hatton, J. W., & Khunti, K. (2017) · Diabetologia · doi:10.1007/s00125-017-4235-1 · Cited by 8
“Severe hypoglycaemic episodes have a negative impact on the quality of life of patients with diabetes and are possibly associated with an increased risk of vascular and nonvascular death [2, 3].”
BackgroundSelf-citationField, B. C. T., Nayar, R., Kilvert, A., Baxter, M., Hickey, J., Cummings, M. H., & Bain, S. C. (2018) · Diabetic Medicine · doi:10.1111/dme.13670 · Cited by 6
Jialal, I., & Dhindsa, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.006 · Cited by 6
Bejugam, D., Bu, S., Nguyen, A. N., Yaltaghian, M., & Smolen, K. K. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1586061 · Cited by 5
Camoin, M., Velho, G., Saulnier, P., Potier, L., Abouleka, Y., Carpentier, C., Dubois, S. G., Larroumet, A., Rigalleau, V., Gand, E., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01487-8 · Cited by 7
Advancements in Diabetes Technology Are Outpacing the Evidence
Rickson, M., Wright, E. E., Bindal, A., & Ghonim, L. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0145 · Cited by 7
“25 Investigators not only confirmed the findings reported in the earlier study but also demonstrated that there was no difference in risk between the T1D and T2D cohorts.”
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
“%) and reduction in life expectancy (11 years), with studies estimating a three-fold higher mortality among people with T1DM compared to the general population [248 e 252].”
Bergdal, R., Harjutsalo, V., Groop, P., Mutter, S., & on behalf of the FinnDiane Study Group (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02803-8 · Cited by 6
“Neither does cumulative glycaemic exposure consider the impact of hypoglycaemia which is also associated with increased risk of cardiovascular disease [21].”
Risk Stratification for Older Adults with Myocardial Infarction
Saraf, A. A., & Bell, S. P. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0493-6 · Cited by 5
Iwasaki, S., Kozawa, J., Kimura, T., Fukui, K., Iwahashi, H., Imagawa, A., & Shimomura, I. (2017) · Diabetology International · doi:10.1007/s13340-017-0303-5 · Cited by 6
“cardiovascular disease events [10] and all-cause mortality [10–12] in insulin-treated patients with diabetes.”
BackgroundFatima, T., Sedrakyan, S., Awan, M. R., Khatun, M. K., Rana, D., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.10076 · Cited by 5
“This results in promoting renal excretion of glucose, thereby lowering elevated glucose levels [6].”
BackgroundRodríguez‐Gutiérrez, R., Salcido‐Montenegro, A., González‐González, J. G., & McCoy, R. G. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001906 · Cited by 5
Whitlock, R. H., Raizman, Z., Collister, D., Bernier, K. J., Sigurdson, S. M., Tangri, N., Bohm, C. J., Rigatto, C., Komenda, P. V. J., & Yamamoto, J. M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.05.009 · Cited by 4
Zheng, R., Zeng, X., Shen, R., Wang, Y., Liu, J., & Zhang, M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s501132 · Cited by 6
Fabricius, T. W., Verhulst, C. E. M., Svensson, C. H., Wienberg, M., Duijnhouwer, A. L., Tack, C. J., Kristensen, P. L., de Galan, B. E., & Pedersen‐Bjergaard, U. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16283 · Cited by 4
“Several potentially harmful responses to hypoglycaemia may explain a direct causal relationship with CVD, 5,10 including activation of blood coagulation, 11,12 increased inflammation, 11,13 and endothelial dysfunction.”
Low serum C-reactive protein levels predict 90-day mortality in hypoglycaemic patients
Bonaventura, A., Gallo, F., Carbone, F., Sacchi, G., Liberale, L., Dallegri, F., Maggi, D. C., Montecucco, F., & Cordera, R. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.008 · Cited by 4
Miele, F., Clementi, S., Gennaro, R., Nicolao, I., Romanelli, T., Speese, K., & Piras, E. M. (2019) · JMIR Diabetes · doi:10.2196/11343 · Cited by 6
“In the medium-to-long term, patients with poorly controlled diabetes may develop serious health issues, such as cardiovascular diseases [46,47], retinopathies [48,49], or renal diseases [50,51].”
BackgroundGlucose monitoring in diabetes: from clinical studies to real‐world practice
Sagar, R. C., Abbas, A., & Ajjan, R. (2019) · Practical Diabetes · doi:10.1002/pdi.2215 · Cited by 5
Neue Therapieoptionen mit kontinuierlich gemessenen Glukosedaten – Empfehlungen für die Praxis
Seufert, J., Deiss, D., Gölz, S., Haak, T., Klausmann, G., Kroeger, J., Lobmann, R., Pfeiffer, A. F. H., Schnell, O., Seibold, A., et al. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0978-4537 · Cited by 4
“[47] Khunti K, Davies M, Majeed A et al.”
BackgroundNakashima, K., Okamura, N., Sanefuji, H., & Kaneto, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-58574-7 · Cited by 6
Salawati, E. M. (2021) · Cureus · doi:10.7759/cureus.17586 · Cited by 6
“Hypoglycaemia can be mild or severe, causing serious complications such as cardiac mortality, dementia, seizures, fall-related fractures and death [6,10-12].”
BackgroundType 1 Diabetes and Cardiovascular Health
Pesantez, M., Ebekozien, O. A., & Vendrame, F. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.07.003 · Cited by 5
Excess psychosocial burden in women with diabetes and premature acute coronary syndrome
Peters, T. M., Pelletier, R., Behlouli, H., Rossi, A. M., & Pilote, L. (2017) · Diabetic Medicine · doi:10.1111/dme.13452 · Cited by 5
Zaccardi, F., Husemoen, L. L. N., Thorsted, B. L., Webb, D. R., Paul, S. K., Davies, M. J., & Khunti, K. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.01.006 · Cited by 4
“In large cohorts severe hypoglycaemia has been linked to all-cause and cause-specific mortality [7, 25-27]: it remains”
BackgroundMethodSelf-citationRisk Models and Scores of Cardiovascular Disease in Patients with Diabetes Mellitus
Kostopoulos, G., Antza, C., Doundoulakis, I., & Toulis, K. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201210112743 · Cited by 5
PROGENS-HbA 1c study: safety and effectiveness of premixed recombinant human insulin (Gensulin M30)
Walicka, M., Jozwiak, J. J., Rzeszotarsk, J., Zarzycka-Lindner, G., Zonenberg, A., Bijoś, P., Masierek, M., & Franek, E. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.61910 · Cited by 4
Quirós, C., Viñals, C., Giménez, M., Roca, D., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2019.03.013 · Cited by 7
Efficacy and Cardiovascular Safety of Antidiabetic Medications
Pappachan, J. M. (2021) · Current Drug Safety · doi:10.2174/1574886316666210112153429 · Cited by 6
“However, several observational/ cohort/ retrospective studies, [13-18] revealed possible associations between insulin use and all-cause mortality, major adverse cardiovascular events (MACE), hospitalisation from heart failure, and cancer although with multiple confounding factors such as the amount of insulin exposed,…”
BackgroundGuideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
Diabetes treatment deintensification in nursing homes: When less is more
Lega, I. C., & Rochon, P. A. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17832 · Cited by 6
“Hypoglycemia is an important clinical concern for older adults, associated with an increased risk of stroke, myocardial infarction, heart failure, arrythmias, falls, fractures, cognitive decline, and even death.(25,26,28) Hypoglycemia is increasingly recognized as a complication of diabetes, not just a side effect of…”
BackgroundEzzatvar, Y., López‐Gil, J. F., Sepulveda, R. A. Y., Almonacid, J. G. H., & García‐Hermoso, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1704277 · Cited by 5
Sun, X., Gui, M., Huang, H., Zhao, H., Yan, H., Bian, H., & Gao, X. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.521227 · Cited by 4
Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?
Cole, N. I., Swift, P. A., Suckling, R., & Andrews, P. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.106 · Cited by 3
SFDT1, une cohorte française de suivi de personnes vivant avec un diabète de type 1
Riveline, J., Sablone, L., & Cosson, E. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.04.004 · Cited by 5
Glucagon prescribing and prevention of hospitalization for hypoglycemia in a large health system
Herges, J. R., Haag, J. D., Tarpenning, K. A. K., Mara, K. C., & McCoy, R. G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110832 · Cited by 7
Bhagra, S., Ducharme‐Smith, A., Juntunen, M. B., Liedl, C. P., Golembiewski, E. H., Sundt, W. J. S., Krpata, T. S., Lampman, M. A., Espinoza, A. L., & McCoy, R. R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322177 · Cited by 5
Extra pancreatic synthesis of insulin
Bhattacharya, S., Bank, S., Ghosh, R., & Sinha, A. K. (2016) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000138 · Cited by 3
“Indeed, the systemic hypoglycemia has been reported to be a risk factor for acute coronary syndrome [51,52].”
BackgroundJones, G. C., Khan, J., & Sainsbury, C. A. R. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0940-3 · Cited by 4
“Occurrence of severe hypoglycaemia has demonstrated to be associated with macrovascular events, adverse clinical outcomes and mortality in people with T1DM and T2DM [4, 5].”
BackgroundNon-insulin therapies in addition to insulin in Type 1 DM treatment
Llano, A., & McKay, G. A. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa011 · Cited by 3
Alexopoulos, A., Andersen, A., Donatsky, A. M., Gowda, A., & Buse, J. B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14397 · Cited by 3
Cuscino, N., Castelbuono, S., Centi, C., Tinnirello, R., Cimino, M., Zito, G., Orlando, A., Pinzani, M., Conaldi, P. G., Mattina, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051631 · Cited by 6
“…the precise glycemic control exhibited by a healthy physiological system, leading to hypoglycemic events and long-term complications in many patients [5,6]. β -Cell replacement therapies, such as pancreas or islet transplantation (ITx), are instead considered a promising curative option [7,8].”
Bilal, A., Yi, F., Whitaker, K. J., Khan, Z. A., Pratley, R. E., & Casu, A. (2025) · Diabetes Care · doi:10.2337/dc25-0971 · Cited by 5
Chen, K., Ma, H., Wang, Y., Li, D., Li, J., Huang, Y. L., & Huang, M. (2025) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-025-01402-0 · Cited by 2
Bogaarts, G., Mitter, M., Bailey, T. S., Glatzer, T., & Theodorou, D. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113188 · Cited by 2
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 4
Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!
Kabadi, U. M. (2016) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2016.62013 · Cited by 2
Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response
Nandakumar, M., Moin, A. S. M., Ramanjaneya, M., Al‐Qaissi, A., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14716 · Cited by 3
“Regardless of cause, recurrent severe hypoglycaemia is associated with cardiovascular and cerebrovascular disease and may result in death.(22,23)”
BackgroundSevere hypoglycemia and cardiovascular disease
Tak, S., & Jain, A. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100357 · Cited by 2
Canecki-Varžić, S., Prpić-Kriẑevac, I., Berković, M. C., Rahelić, D., Schönberger, E., Gradišer, M., & Bilić-Čurčić, I. (2023) · Medicina · doi:10.3390/medicina59111893 · Cited by 3
“However, good glycemic regulation and treatment of hyperglycemia in patients on MDI or insulin pumps can at the same time result in hypoglycemia with adverse clinical outcomes [2].”
BackgroundRode, M. M., Boggust, B., Manggaard, J. M., Myers, L. A., Swanson, K. M., & McCoy, R. G. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111741 · Cited by 5
Radwan, M. A., Hasona, N. A., Abdel‐Moneim, A., Rabea, A. M., & Khalil, R. G. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10672-3 · Cited by 3
Lin, Y., Chen, C., Huang, L.-Y., Chen, B., Shao, Y. J., & Huang, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-10215-7 · Cited by 3
“Subsequent observational studies confirmed that severe hypoglycemia may contribute to an increased risk of mortality and cardiovascular events 4,5 .”
Hypoglycemic Morbidity and Mortality in Diabetes
Son, J. W. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.1.17 · Cited by 2
Dreyer, M. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0112-7 · Cited by 2
“Ausgewertet wurden 3260 Patienten mit Diabetes mellitus Typ 1 und 2 über den Zeitraum von 2001–2010 aus einem englischen Register [12].”
InfluentialChaves, W. G., Martínez, L., Díaz, D., Hernández, D., & Sanabria, M. C. (2019) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.6.4.545 · Cited by 4
Singh, A. K., & Singh, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108648 · Cited by 2
DuVall, M. A., Coulter, C. E., Gosey, J. L., Herrera, M. J., Hill, C. M., Jariwala, R. R., Maisano, L. E., Moldovan, L. A., Morrison, C. D., Nwabueze, N. V., et al. (2021) · Autonomic Neuroscience · doi:10.1016/j.autneu.2021.102853 · Cited by 2
Papachristoforou, E., Kountouri, A., Maratou, E., Kouretas, D., Skaperda, Z., Tsoumani, M. E., Efentakis, P., Ikonomidis, I., Lambadiari, V., & Makrilakis, K. (2022) · Healthcare · doi:10.3390/healthcare10081509 · Cited by 5
A novel hypoglycemia alarm framework for type 2 diabetes with high glycemic variability
Wang, X., Yang, Z., Ma, N., Sun, X., Li, H., Zhou, J., & Yu, X. (2023) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.3799 · Cited by 2
Giménez, M., Amor, A. J., Quirós, C., & Conget, I. (2015) · Diabetes Care · doi:10.2337/dc15-0271 · Cited by 2
Achievement of ABC Goals in Type 2 Diabetes in Real-life
Chandalia, H. B., Jain, J. D., & Chandalia, S. H. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0730 · Cited by 1
Zhang, Y., Hu, X., Xu, W., Chen, Y., Guo, X., Liu, S.-H., & Gao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.104290 · Cited by 1
Ginjupalli, M., Jayakumar, J., Forlemu, A. N., Sharma, A. B., Bandaru, P. K. R., Kumar, V., Nalluri, K. S. D., & Reddy, M. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16040036 · Cited by 1
“Moreover, hypoglycemia in hospitalized patients has been consistently linked to prolonged hospital stays and increased healthcare charges, even after adjusting for comorbidities [26].”
Adrenaline is a prominent driver of inflammatory responses following hypoglycaemia
Mustafajev, I. F., Hendriksz, M. S., Stienstra, R., Tack, C. J., de Galan, B. E., & Meijer, R. I. (2026) · Diabetologia · doi:10.1007/s00125-026-06667-9 · Cited by 1
“Frequent hypoglycaemic episodes have been associated with a twofold increase in cardiovascular events, independent of other risk factors and despite achieving good glycaemic management [4, 5].”
An overview of the role of platelets in vascular disease associated with diabetes mellitus
Panou, T., Popovic, D. S., Mikhailidis, D. P., & Παπάνας, Ν. (2026) · HORMONES · doi:10.1007/s42000-026-00760-9 · Cited by 1
Heinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
“Weiterhin sollte bei der Festlegung der individuel-len Therapiestrategie besonderes Augenmerk auf die Vermeidung von Hypoglykämien gelegt werden, da gerade schwere Hypoglykämien mit einem höheren kardiovaskulären Risiko assoziiert sind [119–121].”
Vergès, B. L. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.05.022 · Cited by 1
Malek, R., Arbouche, Z., Belhadj, M., Nicolucci, A., & Gari, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30070-6 · Cited by 1
de Oliveira, L. G., & Gabriel, E. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-57084-6_10 · Cited by 1
Recognising the importance of self-management for people with diabetes
Phillips, A. (2019) · British Journal of Healthcare Management · doi:10.12968/bjhc.2017.0030 · Cited by 1
Effects of 25-hydroxyvitamin D on bone microstructure in T2MD rats.
Ge, J., Sun, D., Teng, L., Su, B., Niu, X., & Luo, W. (2018) · Europe PMC (PubMed Central) · Cited by 1
Garavelli, S., Prattichizzo, F., Ceriello, A., Galgani, M., & de Candia, P. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0053 · Cited by 2
“…diseases (CVDs) is well documented (175), with T1D subjects suffering from a decade anticipation of CVDs (by the age of 45 years, the majority of them develops coronary artery calcification) and an almost threefold higher mortality compared with the general population (39, 42, 100, 176).”
Katsarou, D. N., Georga, E. I., Christou, M., Tigas, S. K., Papaloukas, C. L., & Fotiadis, D. I. (2023) · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering · doi:10.1007/978-3-031-34586-9_30 · Cited by 1
Metadata
- Authors
- Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K.
- Affiliations
- University of Leicester (GB)
- Imperial College London (GB)
- Novo Nordisk (Denmark) (DK)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Khunti, Kamlesh
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-09
- Volume
- 38
- Issue
- 2
- Pages
- 316-322
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128592897
- Cited by
- 356
- References
- 32
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 26 · 2023: 34 · 2022: 26 · 2021: 39 · 2020: 33 · 2019: 38 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 20
- FWCI
- 25.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypoglycemia, cardiovascular disease, all-cause mortality, type 1 diabetes, type 2 diabetes, insulin-treated diabetes, cardiovascular events, mortality risk
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, England, Epidemiologic Methods, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.